Grab your favorite coffee. This is where you’ll find all the substance you require, and more.

Cognivia-Narrow-Hero-1
Education

Q&A: Developing a Custom e-Questionnaire Data Management Solution for Clinical Trials

Q&A Interview with Gilles Scuttenaire, Senior Software Engineer In a presentation at BIO IT World 2022, Cognivia’s Gilles Scuttenaire, senior Software Engineer, discussed our custom, end-to-end data management…

Read More
Education

Development of end-to-end data management to improve lead times

Technical poster submitted to the BIO-IT World and presented on May 3rd 2022. The implementation of an optimized data management pipeline might require multiple underlying technical solutions that should integrate perfectly one with another. It can be complicated to find its own path among off-the-shelf…

Read More
Education

Top 3 Risks of Unchecked Placebo Response in Clinical Trials

Placebo response is one of the biggest threats to clinical data analysis– especially when left unchecked. In this blog, we review the top three risks trial scientists must address (and how to address them). 

Read More
Education

How to Use ePRO to Understand the Impact of Decentralized Clinical Trials on Patients

In this article, we will first discuss the rise of DCTs, empowered by technology like ePRO in clinical trials. Then, we will review how related technology can…

Read More
Education

Getting New Pain Drugs to Market: 3 Challenges

Each September, pain advocates and specialists raise awareness about issues facing the millions of people living with chronic pain. One of the most pressing? The lack of treatments available to alleviate suffering.…

Read More
Education

Where Does Placebo Response in Clinical Trials Come From? 6 Influences

Placebo response is a major source of noise in trial data analysis, muddying the results and making it more difficult to detect true treatment effect. We know…

Read More

Let’s help you with your next trial.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.